Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.36 (
hyaluronidase
)
4,606
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Aneurysmal
subarachnoid hemorrhage
remains one of the more devastating forms of stroke due in large part to delayed cerebral ischemia that appears days to weeks following the initial hemorrhage. Therapies exclusively targeting large caliber arterial vasospasm have fallen short, and thus we asked whether capillary dysfunction contributes to delayed cerebral ischemia after
subarachnoid hemorrhage
. Using a mouse model of
subarachnoid hemorrhage
and two-photon microscopy we showed capillary dysfunction unrelated to upstream arterial constriction.
Subarachnoid hemorrhage
decreased RBC velocity by 30%, decreased capillary pulsatility by 50%, and increased length of non-perfusing capillaries by 15%. This was accompanied by severe brain hypoxia and neuronal loss. Hyaluronidase, an enzyme that alters capillary blood flow by removing the luminal glycocalyx, returned RBC velocity and pulsatility to normal. Hyaluronidase also reversed brain hypoxia and prevented neuron loss typically seen after
subarachnoid hemorrhage
. Thus,
subarachnoid hemorrhage
causes specific changes in capillary RBC flow independent of arterial spasm, and
hyaluronidase
treatment that normalizes capillary blood flow can prevent brain hypoxia and injury after
subarachnoid hemorrhage
. Prevention or treatment of capillary dysfunction after
subarachnoid hemorrhage
may reduce the incidence or severity of
subarachnoid hemorrhage
-induced delayed cerebral ischemia.
...
PMID:Cerebral microcirculatory failure after subarachnoid hemorrhage is reversed by hyaluronidase. 2666 Nov 83